Post-marketing Surveillance Study of Adalimumab (Humira®) for Non-infectious Intermediate, Posterior, or Panuveitis Patients

CompletedOBSERVATIONAL
Enrollment

158

Participants

Timeline

Start Date

January 25, 2018

Primary Completion Date

July 16, 2020

Study Completion Date

July 16, 2020

Conditions
Non-infectious Intermediate, Posterior and Panuveitis
Trial Locations (17)

10380

Inje University Ilsan Paik Hos /ID# 204543, Goyang

13620

Seoul National Univ Bundang ho /ID# 201657, Seongnam

16499

Ajou University Hospital /ID# 201516, Suwon

21388

HanGil Eye Hospital /ID# 201655, Bupyeong

28644

Chungbuk National Univ Hosp /ID# 204544, Cheongju-si

31151

Soon Chun Hyang University Cheonan Hospital /ID# 204551, Cheonan

42415

Yeungnam University Med Ctr /ID# 201361, Daegu

48972

Maryknoll Medical Center /ID# 201370, Busan

49241

Pusan National University Hosp /ID# 202026, Busan

54538

Wonkwang University Hospital /ID# 204545, Iksan

61453

Chosun University Hospital /ID# 204542, Gwangju

06198

Nune Eye Hospital /ID# 211613, Seoul

06273

Gangnam Severance Hospital /ID# 202027, Seoul

06351

Samsung Medical Center /ID# 201515, Seoul

06023

Apgujung St. Mary's Eye Center /ID# 210721, Gangnam-gu

03080

Seoul National University Hospital /ID# 201656, Seoul

07301

Kim's Eye Hospital /ID# 205685, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AbbVie

INDUSTRY